BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 29, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Otelixizumab: Additional Phase II data

Additional data from a double-blind, placebo-controlled, European Phase II trial in 64 evaluable patients with Type I diabetes showed that otelixizumab given for 6 days preserved beta cell function and delayed the rise in insulin requirements for up to 48 months. Data were published...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >